How Will the Market React to CureVac BV (CVAC) Stock Getting a Bearish Rating

CureVac BV (CVAC) stock is down 13.06% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

CureVac BV has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CVAC!

See Full CVAC Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CVAC Stock Today?

CureVac BV (CVAC) stock is trading at $2.93 as of 10:09 AM on Wednesday, Mar 20, a drop of -$0.02, or -0.51% from the previous closing price of $2.94. The stock has traded between $2.76 and $2.94 so far today. Volume today is less active than usual. So far 272,744 shares have traded compared to average volume of 843,797 shares. To screen for more stocks like CureVac BV click here.

More About CureVac BV

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases. Click Here to get the full Stock Report for CureVac BV stock.